Dermatitis, Seborrheic clinical trials
The registry lists 58 studies for Dermatitis, Seborrheic across more than 10 countries. 7 are recruiting or about to start. 46 of them are mainly about Dermatitis, Seborrheic (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-30.
Get an email when these change. Save the Dermatitis, Seborrheic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Arcutis Biotherapeutics, Inc. (3) · Pierre Fabre Dermo Cosmetique (3) · Moberg Pharma AB (2) · Icahn School of Medicine at Mount Sinai (2) · Kamedis Ltd. (1) · NovoBliss Research Pvt Ltd (1) · Chelsea and Westminster NHS Foundation Trust (1) · Dermatology Specialists Research (1)
What is being tested here
Drugs under test in Dermatitis, Seborrheic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Ketoconazole | 1 | 0 | 3 |
| Bacitracin | 1 | 0 | 1 |
| Polymyxin B | 1 | 0 | 1 |
| Neomycin | 1 | 0 | 1 |
| Itraconazole | 1 | 0 | 1 |
| ARQ-154 | 0 | 1 | 3 |
| Tacrolimus | 0 | 1 | 2 |
| Terbinafine | 0 | 0 | 1 |
| Ruxolitinib | 0 | 0 | 1 |
| Cannabidiol | 0 | 0 | 1 |
Drug classes tested here Calcineurin inhibitors 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3, phase 3 first
- Jun 2027Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis · Phase 3 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Dec 2026ZYG24002 Lotion to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Adult Patients With Mild to Moderate Seborrheic Dermatitis · Sinomune Pharmaceutical Co., Ltd
- Feb 2027TRIDERM D.S. Crema Normalizzante for Neonatal Hyperseborrhea (Cradle Cap) and Associated Cutaneous Manifestations of Mild-to-Moderate Seborrheic Dermatitis in Children Aged 0 to 3 Years · ICIM International S.r.l.
Who these studies take
Of the 4 Dermatitis, Seborrheic studies recruiting now, 1 (25%) set no upper age limit and 3 (75%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 1 (25%) for men only; 2 (50%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 3 (75%) | 4 (100%) |
| 30 | 3 (75%) | 4 (100%) |
| 40 | 3 (75%) | 4 (100%) |
| 50 | 3 (75%) | 4 (100%) |
| 65 | 3 (75%) | 3 (75%) |
| 75 | 1 (25%) | 1 (25%) |
| 85 | 1 (25%) | 1 (25%) |
Across all 58 studies, recruiting or not: 41% stop at 75 or younger and 31% at 65; 22% take children; 9% are for women only and 3% for men only; 29% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 50 of 58. Browse all 58 → or search them.
- TRIDERM D.S. Crema Normalizzante for Neonatal Hyperseborrhea (Cradle Cap) and Associated Cutaneous Manifestations of Mild-to-Moderate Seborrheic Dermatitis in Children Aged 0 to 3 YearsNot yet recruitingNCT07860788Not applicable1 country
- Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic DermatitisNot yet recruitingNCT07683806Phase 31 country
- The Effectiveness of Itraconazole Pulse Therapy vs Topical 2% Ketoconazole in the Treatment of Moderate to Severe Seborrheic Dermatitis of Scalp.RecruitingNCT07734441Early Phase 11 country
- ZYG24002 Lotion to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Adult Patients With Mild to Moderate Seborrheic DermatitisRecruitingNCT07404033Phase 11 country
- A Study on Scalp Health and Integrated Scalp Management Protocols for Hair Transplant PatientsRecruitingNCT07641686Not applicable1 country
- Sebum Metabolomics and Lipidomics for Clinical ApplicationsNot yet recruitingNCT07549828Not applicable
- The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic DermatitisRecruitingNCT05942248Not applicable1 country
- Topical Terbinafine Versus Hydrocortisone Combined With Oral Itraconazole for Seborrheic DermatitisCompletedNCT07906886Phase 41 country
- Ozonated Oil Emulsion for Seborrhea in WomenCompletedNCT07559617Not applicable1 country
- Cleansing Device for the Treatment of Scalp and Hair ConditionsTerminatedNCT05319444Not applicable1 country
- Effect of 0.75% Piroctone Olamine Shampoo on the Hair and Scalp Microbiota of Hijab-Wearing Women With Seborrheic Dermatitis in IndonesiaCompletedNCT07802808Phase 41 country
- PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular RosaceaTerminatedNCT06013371Phase 21 country
- Safety and Efficacy of a Topical Cream in Mild-to-Moderate Seborrheic DermatitisCompletedNCT07063615Not applicable1 country
- Efficacy of an Antioxidant Moisturizing Serum for Mild to Moderate Seborrheic DermatitisCompletedNCT07433907Not applicable1 country
- A 4-weeks Comparative Study of Cosmetic Product Versus Standard Medical Care in Subjects With Seborrheic DermatitisCompletedNCT07576023Not applicable1 country
- Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and DermatologistsCompletedNCT074289151 country
- Phenotypic and Functional Profile of Peripheral Blood Lymphomonocytes in Seborrheic Dermatitis.CompletedNCT072974461 country
- Ruxolitinib in Seborrheic DermatitisCompletedNCT05787860Phase 21 country
- Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and AdultCompletedNCT03830177Phase 1/21 country
- Efficacy of a Cosmetic Shampoo RV3438G in Reccurent Squamous StatesCompletedNCT065789621 country
- A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's DiseaseCompletedNCT03582137Phase 21 country
- Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic DermatitisCompletedNCT04445987Phase 21 country
- Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory DermatosisCompletedNCT04472546Not applicable1 country
- Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing ExacerbationTerminatedNCT01315951Not applicable1 country
- Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)CompletedNCT04973228Phase 32 countries
- Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic DermatitisCompletedNCT04091646Phase 22 countries
- A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the FaceCompletedNCT00408330Phase 21 country
- Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of ScalpCompletedNCT051051391 country
- A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic DermatitisCompletedNCT00403559Phase 21 country
- HIV Indicator Diseases in Hospital and Primary CareStatus unknownNCT052254931 country
- A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in EuropeCompletedNCT049251805 countries
- A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic DermatitisCompletedNCT03567980Phase 41 country
- DUS on the Prescribing Indications for CPA/EE in 5 European CountriesCompletedNCT024942971 country
- Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic DermatitisCompletedNCT03114111Early Phase 11 country
- Effects on the Scalp Microbiota of a 1% Selenium Disulfide and 1% Salicylic Acid Shampoo After 2% Ketaconazole Foaming Gel Treatment for Scalp Seborrheic DermatitisCompletedNCT04057950Not applicable1 country
- Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic DermatitisCompletedNCT00862654Phase 35 countries
- Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis PatientsCompletedNCT038074531 country
- Omiganan Twice a Day (BID) in Patients With Facial Seborrheic DermatitisStatus unknownNCT03688971Phase 21 country
- Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic DermatitisCompletedNCT02004860Phase 31 country
- Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% ShampooCompletedNCT01203189Not applicable1 country
- Neurobiology of the Scalp in Seborrheic DermatitisCompletedNCT023498541 country
- Promiseb Topical Cream for Cradle CapCompletedNCT01214434Phase 41 country
- STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%CompletedNCT00703846Phase 4
- A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic DermatitisCompletedNCT02749383Phase 2
- Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic DermatitisCompletedNCT02656368Not applicable
- Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male VolunteersCompletedNCT01254162Phase 21 country
- Safety and Efficacy Study in Subjects With Seborrheic DermatitisCompletedNCT01703793Phase 21 country
- Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic DermatitisCompletedNCT01591070Phase 41 country
- HairMax LaserComb Open Label Study to Treat Seborrheic DermatitisCompletedNCT00830908Not applicable1 country
- HIV Indicator Diseases Survey Across Europe - UK ArmStatus unknownNCT011964681 country